Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Margaret Locke, Paavani S. Reddy & Sherif M. Badawy. (2022) Adherence to Iron Chelation Therapy among Adults with Thalassemia: A Systematic Review. Hemoglobin 46:4, pages 201-213.
Read now
Read now
Racha Halawi, Irene Motta, Ali Taher & Maria Domenica Cappellini. (2016) Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes. Expert Opinion on Orphan Drugs 4:6, pages 677-686.
Read now
Read now
Maria Domenica Cappellini, Vip Viprakasit & Ali T Taher. (2014) An overview of current treatment strategies for β-thalassemia. Expert Opinion on Orphan Drugs 2:7, pages 665-679.
Read now
Read now
Ali T Taher, Sally Temraz & M Domenica Cappellini. (2013) Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia. Expert Review of Hematology 6:5, pages 495-509.
Read now
Read now
Janet L Kwiatkowski. (2011) Management of transfusional iron overload – differential properties and efficacy of iron chelating agents. Journal of Blood Medicine 2, pages 135-149.
Read now
Read now
Articles from other publishers (15)
Yen-Chien Lee, Chi-Tai Yen, Yen-Ling Lee & Rong-Jane Chen. (2022) Thalassemia Intermedia: Chelator or Not?. International Journal of Molecular Sciences 23:17, pages 10189.
Crossref
Crossref
Viktor A. Timoshnikov, Olga Yu. Selyutina, Nikolay E. Polyakov, Victoria Didichenko & George J. Kontoghiorghes. (2022) Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine. International Journal of Molecular Sciences 23:3, pages 1247.
Crossref
Crossref
Noppacharn Uaprasert, Sudarat Satitthummanid, Benjaporn Akkawat, Pranee Sutcharitchan & Ponlapat Rojnuckarin. (2019) Vascular and hemostatic alterations associated with pulmonary hypertension in β-thalassemia hemoglobin E patients receiving regular transfusion and iron chelation. Thrombosis Research 174, pages 104-112.
Crossref
Crossref
Amira A. Adly & Eman A. Ismail. (2018) Management of Children With β-Thalassemia Intermedia: Overview, Recent Advances, and Treatment Challenges. Journal of Pediatric Hematology/Oncology 40:4, pages 253-268.
Crossref
Crossref
Shing Chan, Qizhou Lian, Mei-Pian Chen, Dan Jiang, Jolie T.K. Ho, Yiu-Fai Cheung & Godfrey Chi-Fung Chan. (2018) Deferiprone inhibits iron overload-induced tissue factor bearing endothelial microparticle generation by inhibition oxidative stress induced mitochondrial injury, and apoptosis. Toxicology and Applied Pharmacology 338, pages 148-158.
Crossref
Crossref
Ali T. Taher, M. Domenica Cappellini, Yesim Aydinok, John B. Porter, Zeynep Karakas, Vip Viprakasit, Noppadol Siritanaratkul, Antonis Kattamis, Candace Wang, Zewen Zhu, Victor Joaquin, Marie José Uwamahoro & Yong-Rong Lai. (2016) Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells, Molecules, and Diseases 57, pages 23-29.
Crossref
Crossref
Giuseppina Calvaruso, Angela Vitrano, Rosario Di Maggio, Eliana Lai, Grazia Colletta, Alessandra Quota, Calogera Gerardi, Luciana Concetta Rigoli, Massimiliano Sacco, Lorella Pitrolo & Aurelio Maggio. (2015)
Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5‐year long‐term
I
talian multicenter randomized clinical trial
. American Journal of Hematology 90:7, pages 634-638.
Crossref
Crossref
Afif R. Harb, Antoine N. Saliba & Ali T. Taher. (2014) Non-Transfusion Dependent Thalassemia: Translating Evidence to Guidelines. Thalassemia Reports 4:3, pages 4863.
Crossref
Crossref
Jeffrey C. Robinson, Brian B. Graham, Tracey C. Rouault & Rubin M. Tuder. (2014) The Crossroads of Iron with Hypoxia and Cellular Metabolism. Implications in the Pathobiology of Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology 51:6, pages 721-729.
Crossref
Crossref
Ali T. Taher & Maria Domenica Cappellini. (2014) Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide. Drugs 74:15, pages 1719-1729.
Crossref
Crossref
Ali T. Taher, Khaled M. Musallam, Vip Viprakasit, John B. Porter & Maria Domenica Cappellini. (2014) Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. Blood Cells, Molecules, and Diseases 52:2-3, pages 88-90.
Crossref
Crossref
Vip Viprakasit & Worapant Kriengsoontornkij. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
419
433
.
Ali T. Taher, John B. Porter, Vip Viprakasit, Antonis Kattamis, Suporn Chuncharunee, Pranee Sutcharitchan, Noppadol Siritanaratkul, Renzo Galanello, Zeynep Karakas, Tomasz Lawniczek, Dany Habr, Jacqueline Ros, Zewen Zhu & M. Domenica Cappellini. (2013) Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of Hematology 92:11, pages 1485-1493.
Crossref
Crossref
Ali T. Taher, Vip Viprakasit, Khaled M. Musallam & M. Domenica Cappellini. (2013) Treating iron overload in patients with non‐transfusion‐dependent thalassemia. American Journal of Hematology 88:5, pages 409-415.
Crossref
Crossref
Ali T. TaherJohn PorterVip ViprakasitAntonis KattamisSuporn ChuncharuneePranee SutcharitchanNoppadol SiritanaratkulRenzo GalanelloZeynep KarakasTomasz LawniczekJacqueline RosYiyun Zhang, Dany Habr & Maria Domenica Cappellini. (2012) Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 120:5, pages 970-977.
Crossref
Crossref